Immune checkpoint inhibitors in the treatment of advanced mucosal melanoma.

IF 1 Q4 ONCOLOGY Melanoma Management Pub Date : 2017-09-01 Epub Date: 2017-10-04 DOI:10.2217/mmt-2017-0014

James C Kuo

引用次数: 8

Abstract

Immunotherapy with immune checkpoint inhibitors is the standard of care in the treatment of advanced melanoma. Treatment outcome of these agents is less defined for the rare subtype of mucosal melanoma. In this single-institutional case series, the objective response rate was low at 11.8%, but durable response was seen, including a complete response to first-line ipilimumab and to second-line pembrolizumab. Survival remained poor; at the median follow-up of 10.1 months, the median progression-free survival and overall survival were 3.1 and 8.8 months respectively. Nevertheless, among the few responders, survival of up to 56+ months was observed. Other treatment strategies need to be explored to improve treatment outcome for this rare subtype.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

免疫检查点抑制剂治疗晚期粘膜黑色素瘤。

免疫检查点抑制剂的免疫疗法是治疗晚期黑色素瘤的标准护理。对于罕见的粘膜黑色素瘤亚型，这些药物的治疗效果尚不明确。在这个单一机构的病例系列中，客观缓解率很低，为11.8%，但可以看到持久的缓解，包括对一线伊匹单抗和二线派姆单抗的完全缓解。生存率仍然很低;中位随访10.1个月时，中位无进展生存期和总生存期分别为3.1个月和8.8个月。然而，在少数应答者中，观察到的生存期长达56个月以上。需要探索其他治疗策略来改善这种罕见亚型的治疗效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Melanoma Management ONCOLOGY-

CiteScore

5.10

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Skin cancer is on the rise. According to the World Health Organization, 132,000 melanoma skin cancers occur globally each year. While early-stage melanoma is usually relatively easy to treat, once disease spreads prognosis worsens considerably. Therefore, research into combating advanced-stage melanoma is a high priority. New and emerging therapies, such as monoclonal antibodies, B-RAF and KIT inhibitors, antiangiogenic agents and novel chemotherapy approaches hold promise for prolonging survival, but the search for a cure is ongoing. Melanoma Management publishes high-quality peer-reviewed articles on all aspects of melanoma, from prevention to diagnosis and from treatment of early-stage disease to late-stage melanoma and metastasis. The journal presents the latest research findings in melanoma research and treatment, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. Key topics covered include: Risk factors, prevention and sun safety education Diagnosis, staging and grading Surgical excision of melanoma lesions Sentinel lymph node biopsy Biological therapies, including immunotherapy and vaccination Novel chemotherapy options Treatment of metastasis Prevention of recurrence Patient care and quality of life.